Is the recent volume decrease indicative of a long-term trend, and when might patient volume increase, especially with easier comparisons in the second half?

The change in volume aligns with past seasonal patterns, and the company expects full-year volumes to be flat to slightly down. Management does not believe it's an ongoing trend, citing the high-acuity focus of neonatology and the potential for telehybrid medicine to address care deserts. “Well, the change in volume is pretty much on trend with past seasonal patterns. We expect for the year that we'll be overall flat in volume to maybe slightly down. As for an ongoing trend, we don't know.”

Can the 4% pricing increase be further broken down by the contributions of RCM collections, payer mix, and acuity?

RCM collections were the largest contributor, followed closely by payer mix, and then acuity. These three factors collectively accounted for approximately 95% of the pricing increase in the quarter. While RCM tailwinds are expected to dissipate in H2, acuity is anticipated to remain a positive driver. “The biggest contributor is the RCM collections. And then really kind of coming in a close second is the payer mix impact. And then rearing it up there is the acuity. So those three drivers are about 95% of the pricing for the quarter.”

What is the company's activity and pricing strategy regarding acquisitions, and are all dispositions complete?

All dispositions are complete. The company sees numerous acquisition opportunities with fair pricing, particularly within women's and children's medicine. They are also open to collaborating with capital partners for larger strategic opportunities. “All the dispositions are definitely behind us. All the dispositions are behind us, and then all that MARC cover... we do see a lot of opportunities where pricing is fair.”

Pediatrix Medical Group (MD) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 4, 2026

Source: earnings call transcript

Executive summary

Pediatrix Medical Group Q2 FY26 — Solid Adjusted EBITDA and Share Buybacks

Pediatrix Medical Group delivered a solid second quarter, meeting expectations with strong adjusted EBITDA and reaffirming its full-year outlook. The company continues to leverage its financial strength for share repurchases and strategic growth opportunities in women's and children's medicine, including telehybrid services. While facing slight volume declines, favorable pricing dynamics from RCM collections, payer mix, and acuity offset these pressures.

Highlights

Adjusted EBITDA reached $76 million, aligning with expectations for the quarter.
The company reaffirmed its full-year 2026 adjusted EBITDA outlook of $280 million to $300 million.
Just under 2 million shares were repurchased in the quarter, contributing to a total of 7 million shares bought back since August 2025.
Same unit pricing increased by 4%, driven by strong RCM collections, favorable payer mix, and increased patient acuity.
Payer mix improved by 135 basis points year-over-year and 120 basis points quarter-over-quarter.

Concerns

Modestly lower volumes were observed, primarily in neonatology, with NICU days down 3%.
Same unit patient service volumes decreased by 2% year-over-year.
Practice-level FW&B expenses rose due to increases in salary and malpractice expenses.
G&A expense increased year-over-year, primarily related to executive transition costs.

Guidance & targets

Category	Target	Timeline	Confidence
Adjusted EBITDA	$280 million to $300 million high materiality	FY26	High
Adjusted EBITDA	fairly ratable medium materiality	H2 FY26	Medium

Deals & partnerships

Various Recent acquisitions contributing to non-Same Unit activity

Consolidated revenue increased by 4%, driven by non-Same Unit activity, primarily recent acquisitions.

Outside JV and capital investors Exploring potential opportunities to augment strengths in women's and children's medicine

Actively looking at possible growth avenues within women's and children's medicine, including potential opportunities to augment our strengths by working with outside JV and capital investors.

Risks & headwinds

Modestly lower volumes Q2 FY26

NICU days down 3%; Same unit patient service volumes down 2%

Mitigation:Offset by strong RCM collections, favorable payer mix, and increased patient acuity; company expects full year volumes to be flat to slightly down and does not see it as an ongoing trend.

Increased practice-level expenses Q2 FY26

FW&B expenses increased year over year

Mitigation:Salary growth remained in a tight band (3% to 3.5%); tight controls in place.

Dissipation of RCM collections tailwind second half of 2026

RCM collections tailwind will begin to dissipate

Mitigation:Anticipate acuity will continue to be a positive factor for pricing.

Increased G&A expense Q2 FY26

G&A expense increased to $5.8 million compared to $5.3 million in prior year

Mitigation:Primarily related to one-time-ish executive transition costs; expected to step down in H2.

What to watch in Q3 FY26

RCM collections tailwind

Second half of 2026

Current Biggest contributor to 4% same unit pricing growth

Target Dissipation of tailwind

Why it matters

RCM collections have been a primary driver of pricing growth; its dissipation could impact future revenue growth.

The biggest contributor is the RCM collections... we do anticipate that the RCM collections piece that we've been seeing that tailwind will begin to dissipate in the last in the second half of 2026.

Find out whether MD delivers this. Inve re-checks your case every morning.

Q&A highlights

Why is Pediatrix's payer mix stable compared to peers, what consumer trends drive it, and what are the expectations for H2?

Management attributes payer mix stability to the high value of health insurance for pregnant individuals. They have not observed the negative effects seen by other healthcare companies and see no signs of change to date, despite broader concerns about subsidy lapses.

“We have not seen the same effect that others have experienced. You know, we can guess that it has something to do with the fact that if you're pregnant, then the relative value of the pregnancy is going to be higher. of insurance is a lot greater for you than it might be for somebody else.”

asked by Matthew Mardula · answered by Mark Ordan

2 min read 5 chapters

Detailed narrative

Strategic Focus on Telehybrid Medicine

Pediatrix is actively developing a significant telehybrid medicine function to complement its physical services nationwide. This initiative leverages the company's extensive footprint, including over 170 Maternal Fetal Medicine (MFM) specialists and more than 360 Neonatal Intensive Care Units (NICUs) across 32 states.

Management believes that combining telemedicine with physical patient visits offers a superior model, enhancing access to care while ensuring hands-on intervention when necessary, particularly for high-acuity patients.

OBH Footprint Expansion and Growth Avenues

The company is expanding its Obstetric Hospitalist (OBH) footprint, capitalizing on its established relationships with over 400 hospitals. Pediatrix has recruited specialized leaders to drive growth in both telehybrid medicine and OBH services. Beyond organic growth, the company is actively exploring external growth avenues within women's and children's medicine, including potential acquisitions and collaborations with joint venture and capital investors, seeking opportunities that offer clear operating and financial benefits.

Capital Allocation and Financial Strength

Pediatrix maintains a strong balance sheet, reporting a cash balance of $285 million and total debt of $584 million, resulting in net debt of just over $295 million. This financial strength supports consistent investment in practices, quality programs, research, and growth initiatives.

The company continues its share repurchase program, having bought back just under 2 million shares in the quarter and 7 million shares since August 2025, reducing shares outstanding to 81 million.

Pricing Dynamics and Key Drivers

Same unit pricing increased by 4% in the second quarter, primarily attributed to strong revenue cycle management (RCM) cash collections, a favorable payer mix, and an ongoing rise in patient acuity, particularly within neonatology. Payer mix showed significant improvement, up 135 basis points year-over-year and 120 basis points quarter-over-quarter.

While the tailwind from RCM collections is expected to dissipate in the second half of 2026, management anticipates acuity will remain a positive pricing factor.

Volume Trends and Outlook

The company experienced modestly lower volumes, with NICU days down 3% and same unit patient service volumes down 2%. These declines were attributed to a tough prior-year comparison and typical seasonal patterns. Despite the current decrease, management does not view this as a long-term trend, expecting overall volumes for the full year to be flat to slightly down.

The high-acuity nature of their neonatology services and the potential for telehybrid medicine to reach underserved areas are seen as mitigating factors.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.